Table 5 Quantitative comparison of antimicrobial prescriptions before and after NTM acquisition
From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis
Patients with Slow-growing NTM (N = 17) | Patients with Rapidly Growing NTM (N = 8) | |||||||
|---|---|---|---|---|---|---|---|---|
Before | After | Before | After | |||||
N | Median (range) | Median (range) | P-value | N | Median (range) | Median (range) | P-value | |
Penicillins/Beta lactamase | 12 | 0.5 (0–3) | 4 (0–9) | 0.010 | 4 | 1.5 (0.2) | 1.5 (1.6) | 0.65/0.41 |
Cephalosporin | 5 | 2 (0–5) | 1 (0–2) | 0.99 | 2 | 1 (0–2) | 13.5 (0–27) | 0.66 |
Glycopeptide a | – | – | – | – | 1 | 0 | 2 | – |
Carbapenems | 3 | 0 (0–0) | 2 (1–8) | 0.11 | 2 | 0.5 (0–1) | 5.5 (0–11) | 0.66 |
Monobactam b | 2 | 0.5 (0–1) | 0.5 (0–1) | 0.99 | 3 | 0 (0–0) | 2 (1–3) | 0.11 |
Aminoglycosides | 11 | 1 (0–5) | 3 (0–10) | 0.20 | 5 | 2 (0–5) | 5 (2–18) | 0.18 |
Macrolides | 7 | 0 (0–0) | 5 (1–8) | 0.018 | 5 | 0 (0–2) | 3 (1–17) | 0.042 |
Lincosamides c | 2 | 0 (0–0) | 1 (1–1) | 0.16 | 1 | 1 | 0 | 0.32 |
Oxazolidinones d | 1 | 0 | 1 | 0.32 | 1 | 0 | 1 | 0.32 |
Fluoroquinolones | 9 | 2 (0–4) | 2 (0–4) | 0.99 | 6 | 0.5 (0–2) | 4.5 (0–26) | 0.12 |
Antifolates e | 8 | 1 (0–7) | 1 (0–13) | 0.40 | 4 | 1 (0–4) | 2 (1–4) | 0.41 |
Rifamycins f | 5 | 0 (0–0) | 5 (2–7) | 0.042 | 0 | – | – | – |